Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Keywords
Acute Exacerbation of Chronic Obstructive Pulmonary Disease During the Peri-Discharge Period, Guben Kechuan Granules
Brief summary
Chronic Obstructive Pulmonary Disease (COPD) is one of the most common chronic airway diseases in China. Western medicine treatments have good clinical efficacy, but their effectiveness is limited in patients with Acute Exacerbation of COPD (AECOPD) during the peri-discharge period. Recurrent acute exacerbations remain an urgent clinical challenge to address. Traditional Chinese Medicine (TCM) has certain advantages in treating chronic airway diseases. Among them, Guben Kechuan Granules are widely used in respiratory diseases such as emphysema and COPD. However, high-level evidence for the use of Guben Kechuan Granules in patients with AECOPD during the peri-discharge period is currently lacking, and its mechanism of action has not been fully clarified.This study enrolled 126 patients with AECOPD during the peri-discharge period, who were randomly divided into the experimental group and the control group using a central randomization system. Both groups received treatment under the guidance of clinical guidelines, and the experimental group was additionally administered Guben Kechuan Granules. Follow-up assessments were conducted at 4 weeks, 8 weeks, and 12 weeks after treatment initiation, with efficacy indicators evaluated at 12 weeks. The primary efficacy endpoint was the improvement in Forced Expiratory Volume in 1 second (FEV1), while the secondary endpoints included the St. George's Respiratory Questionnaire (SGRQ), Modified Medical Research Council (mMRC) Dyspnea Scale, COPD Assessment Test (CAT), and 6-Minute Walk Test (6MWT). This study aims to scientifically evaluate the clinical efficacy of Guben Kechuan Granules in treating AECOPD during the peri-discharge period and generate high-quality clinical evidence.By detecting COPD-related inflammatory indicators, T-cell subsets, transcriptomics, serum metabolomics, and lipidomics, the mechanism of action of Guben Kechuan Granules in this patient population will be clarified. The study intends to elucidate its molecular mechanism of inhibiting inflammatory cascades through metabolic regulation, and screen metabolite marker clusters that can predict the response to integrated TCM and Western medicine treatment, thereby providing objective evidence for individualized precision intervention strategies.
Interventions
DRUGGuben Kechuan Granules group
On the basis of receiving conventional treatment (referring to the 2025 GOLD Guidelines) and health education, patients in the Guben Kechuan Granules group were administered Guben Kechuan Granules. The granules were dissolved in warm water for oral administration at a dosage of 2 g each time, 3 times a day, for 12 consecutive weeks.
DRUGPlacebo Drug
On the basis of receiving conventional treatment (referring to the 2025 GOLD Guidelines) and health education, patients in the control group were administered placebo. The placebo was dissolved in warm water for oral administration at a dosage of 2 g each time, 3 times a day, for 12 consecutive weeks.
Sponsors
Cuiling Feng
Linfen Central Hospital
Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine
Traditional Chinese Medicine Hospital of Changji Hui Autonomous Prefecture, Xinjiang
Jinan Hospital of Integrated Traditional Chinese and Western Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Meet the diagnostic criteria for Chronic Obstructive Pulmonary Disease (COPD), with lung function classified as Grade II-IV (Groups B and E). * Be in the peri-discharge period of Acute Exacerbation of COPD (AECOPD). * Conform to the Traditional Chinese Medicine (TCM) syndrome of spleen deficiency with excessive phlegm and insecure kidney qi. * Aged 40-75 years, regardless of gender. * Be an inpatient. * Have no prior use of Guben Kechuan Granules. * Be willing to participate in this study and sign the informed consent form.
Exclusion criteria
* Have airflow limitation caused by other respiratory diseases such as bronchial asthma, bronchiectasis, pulmonary tuberculosis, and lung cancer. * Have severe concurrent diseases of the heart, brain, liver, kidney, etc., which render the patient unable to cooperate with exercise. * Have an impaired immune system or be receiving long-term ·immunosuppressive therapy. * Be currently participating in another interventional clinical trial of drugs or medical devices.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Degree of improvement in Forced Expiratory Volume in 1 second (FEV1) | Collected at baseline, 2 weeks post-treatment, 4 weeks post-treatment, 8 weeks post-treatment, and 12 weeks post-treatment | The degree of improvement in Forced Expiratory Volume in 1 second (FEV1) of patients during the study period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| St. George's Respiratory Questionnaire (SGRQ) score | Collected at baseline, 4 weeks post-treatment, 8 weeks post-treatment, and 12 weeks post-treatment | The changes in patients' St. George's Respiratory Questionnaire (SGRQ) scores during the study period. The SGRQ is a validated tool for assessing health-related quality of life in patients with chronic obstructive pulmonary disease. Scores range from 0 to 100, with higher scores indicating worse respiratory-related quality of life. |
| Modified Medical Research Council (mMRC) Dyspnea Questionnaire | Collected at baseline, 4 weeks post-treatment, 8 weeks post-treatment, and 12 weeks post-treatment | The changes in patients' Modified Medical Research Council (mMRC) Dyspnea Questionnaire scores during the study period. The mMRC scale is a 5-point scale (ranging from 0 to 4) used to grade the severity of dyspnea. Higher scores indicate more severe dyspnea. |
| COPD Assessment Test (CAT) Questionnaire | Collected at baseline, 4 weeks post-treatment, 8 weeks post-treatment, and 12 weeks post-treatment | The changes in patients' COPD Assessment Test (CAT) Questionnaire scores during the study period. The CAT is an 8-item questionnaire that measures the impact of COPD on a patient's health status. Scores range from 0 to 40, with higher scores indicating a greater negative impact of COPD on health status. |
| 6-Minute Walk Test (6MWT) | Collected at baseline, 4 weeks post-treatment, 8 weeks post-treatment, and 12 weeks post-treatment | The changes in patients' 6-Minute Walk Test (6MWT) during the study period |
Contacts
CONTACTCuiling Feng
Outcome results
None listed